Literature DB >> 20335584

Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease.

Kitt Falk Petersen1, Sylvie Dufour, Ali Hariri, Carol Nelson-Williams, Jia Nee Foo, Xian-Man Zhang, James Dziura, Richard P Lifton, Gerald I Shulman.   

Abstract

BACKGROUND: Nonalcoholic fatty liver disease is associated with hepatic insulin resistance and type 2 diabetes mellitus. Whether this association has a genetic basis is unknown.
METHODS: In 95 healthy Asian Indian men, a group known to have a high prevalence of nonalcoholic fatty liver disease, we genotyped two single-nucleotide polymorphisms (SNPs) in the gene encoding apolipoprotein C3 (APOC3) that are known to be associated with hypertriglyceridemia (rs2854116 [T-455C] and rs2854117 [C-482T]). Plasma apolipoprotein C3 concentrations, insulin sensitivity, and hepatic triglyceride content were measured. We also measured plasma triglyceride concentrations and retinyl fatty acid ester absorption as well as plasma triglyceride clearance after oral and intravenous fat-tolerance tests. Liver triglyceride content and APOC3 genotypes were also assessed in a group of 163 healthy non-Asian Indian men.
RESULTS: Carriers of the APOC3 variant alleles (C-482T, T-455C, or both) had a 30% increase in the fasting plasma apolipoprotein C3 concentration, as compared with the wild-type homozygotes. They also had a 60% increase in the fasting plasma triglyceride concentration, an increase by a factor of approximately two in the plasma triglyceride and retinyl fatty acid ester concentrations after an oral fat-tolerance test, and a 46% reduction in plasma triglyceride clearance. The prevalence of nonalcoholic fatty liver disease was 38% among variant-allele carriers and 0% among wild-type homozygotes (P<0.001). The subjects with nonalcoholic fatty liver disease had marked insulin resistance. A validation study involving non-Asian Indian men confirmed the association between APOC3 variant alleles and nonalcoholic fatty liver disease.
CONCLUSIONS: The polymorphisms C-482T and T-455C in APOC3 are associated with nonalcoholic fatty liver disease and insulin resistance. 2010 Massachusetts Medical Society

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20335584      PMCID: PMC2976042          DOI: 10.1056/NEJMoa0907295

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  27 in total

1.  Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men.

Authors:  Kitt Falk Petersen; Sylvie Dufour; Jing Feng; Douglas Befroy; James Dziura; Chiara Dalla Man; Claudio Cobelli; Gerald I Shulman
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-17       Impact factor: 11.205

2.  Statins and hepatic steatosis: perspectives from the Dallas Heart Study.

Authors:  Jeffrey D Browning
Journal:  Hepatology       Date:  2006-08       Impact factor: 17.425

3.  APOC3 promoter polymorphisms C-482T and T-455C are associated with the metabolic syndrome.

Authors:  Michael Miller; Jeffrey Rhyne; Hegang Chen; Valerie Beach; Richard Ericson; Kalpana Luthra; Manjari Dwivedi; Anoop Misra
Journal:  Arch Med Res       Date:  2007-03-26       Impact factor: 2.235

4.  Characterization of the sinusoidal transport process responsible for uptake of chylomicrons by the liver.

Authors:  B C Sherrill; J M Dietschy
Journal:  J Biol Chem       Date:  1978-03-25       Impact factor: 5.157

5.  Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice.

Authors:  Y Ito; N Azrolan; A O'Connell; A Walsh; J L Breslow
Journal:  Science       Date:  1990-08-17       Impact factor: 47.728

6.  Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp.

Authors:  M Matsuda; R A DeFronzo
Journal:  Diabetes Care       Date:  1999-09       Impact factor: 19.112

7.  Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy.

Authors:  Kitt Falk Petersen; Elif Arioglu Oral; Sylvie Dufour; Douglas Befroy; Charlotte Ariyan; Chunli Yu; Gary W Cline; Alex M DePaoli; Simeon I Taylor; Phillip Gorden; Gerald I Shulman
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

8.  Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men.

Authors:  Anneli Seppälä-Lindroos; Satu Vehkavaara; Anna-Maija Häkkinen; Takashi Goto; Jukka Westerbacka; Anssi Sovijärvi; Juha Halavaara; Hannele Yki-Järvinen
Journal:  J Clin Endocrinol Metab       Date:  2002-07       Impact factor: 5.958

Review 9.  The role and mode of action of apolipoproteins CIII and AV: synergistic actors in triglyceride metabolism?

Authors:  Ko Willems van Dijk; Patrick C N Rensen; Peter J Voshol; Louis M Havekes
Journal:  Curr Opin Lipidol       Date:  2004-06       Impact factor: 4.776

10.  Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease.

Authors:  Stefano Romeo; Julia Kozlitina; Chao Xing; Alexander Pertsemlidis; David Cox; Len A Pennacchio; Eric Boerwinkle; Jonathan C Cohen; Helen H Hobbs
Journal:  Nat Genet       Date:  2008-09-25       Impact factor: 38.330

View more
  152 in total

Review 1.  The role of muscle insulin resistance in the pathogenesis of atherogenic dyslipidemia and nonalcoholic fatty liver disease associated with the metabolic syndrome.

Authors:  François R Jornayvaz; Varman T Samuel; Gerald I Shulman
Journal:  Annu Rev Nutr       Date:  2010-08-21       Impact factor: 11.848

Review 2.  Genetic background in nonalcoholic fatty liver disease: A comprehensive review.

Authors:  Fabio Salvatore Macaluso; Marcello Maida; Salvatore Petta
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

3.  Hepatobiliary quiz-7 (2013).

Authors:  Swastik Agrawal; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2013-09

4.  Hepatobiliary quiz-3 (2012).

Authors:  Swastik Agrawal; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2012-09

Review 5.  How do elevated triglycerides and low HDL-cholesterol affect inflammation and atherothrombosis?

Authors:  Francine K Welty
Journal:  Curr Cardiol Rep       Date:  2013-09       Impact factor: 2.931

6.  Favorable effect of modest alcohol consumption to fatty liver disease.

Authors:  Masahide Hamaguchi; Takao Kojima
Journal:  World J Gastroenterol       Date:  2013-08-28       Impact factor: 5.742

Review 7.  The global NAFLD epidemic.

Authors:  Rohit Loomba; Arun J Sanyal
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-09-17       Impact factor: 46.802

Review 8.  NAFLD in Asia--as common and important as in the West.

Authors:  Geoffrey C Farrell; Vincent Wai-Sun Wong; Shiv Chitturi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-03-05       Impact factor: 46.802

9.  The Morbidity and Comorbidity of Nonalcoholic Fatty Liver Disease and Different Glucose Intolerance Strata in a Community-Based Chinese Population.

Authors:  Xiuying Zhang; Xianghai Zhou; Xueyao Han; Zuodi Fu; Lianying Wang; Yufeng Li; Linong Ji
Journal:  Metab Syndr Relat Disord       Date:  2020-05-27       Impact factor: 1.894

Review 10.  Endocrine causes of nonalcoholic fatty liver disease.

Authors:  Laura Marino; François R Jornayvaz
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.